A share price of Cytokinetics Inc [CYTK] is currently trading at $63.59, up 2.15%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CYTK shares have gain 9.96% over the last week, with a monthly amount glided 12.91%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Barclays started tracking the stock with Overweight rating on April 24, 2025, and set its price target to $55. On February 07, 2025, Citigroup initiated with a Buy rating and assigned a price target of $86 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $80 on January 22, 2025. RBC Capital Mkts initiated its recommendation with a Outperform and recommended $80 as its price target on November 08, 2024. Goldman downgraded its rating to Neutral for this stock on August 13, 2024, and downed its price target to $60. In a note dated January 24, 2024, UBS downgraded a Neutral rating on this stock and boosted its target price from $61 to $92.
Cytokinetics Inc experienced fluctuations in its stock price throughout the past year between $29.31 and $64.13. Currently, Wall Street analysts expect the stock to reach $86 within the next 12 months. Cytokinetics Inc [NASDAQ: CYTK] shares were valued at $63.59 at the most recent close of the market. An investor can expect a potential return of 35.24% based on the average CYTK price forecast.
Analyzing the CYTK fundamentals
Trailing Twelve Months sales for Cytokinetics Inc [NASDAQ:CYTK] were 85.74M which represents 26714.86% growth. Gross Profit Margin for this corporation currently stands at -2.27% with Operating Profit Margin at -6.38%, Pretax Profit Margin comes in at -7.07%, and Net Profit Margin reading is -7.07%. To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is 3.09 and Total Capital is -0.5. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -2.33.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 62.19 points at the first support level, and at 60.79 for the second support level. However, for the 1st resistance point, the stock is sitting at 64.49, and for the 2nd resistance point, it is at 65.39.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Cytokinetics Inc [NASDAQ:CYTK] is 6.76. Also, the Quick Ratio is 6.76, while the Cash Ratio stands at 0.57. Considering the valuation of this stock, the price to sales ratio is 88.75.
Transactions by insiders
Recent insider trading involved Blum Robert I, President & CEO, that happened on Oct 30 ’25 when 5000.0 shares were sold. Director, WIERENGA WENDELL completed a deal on Oct 27 ’25 to sell 4375.0 shares. Meanwhile, Director WENDELL WIERENGA bought 4375.0 shares on Oct 27 ’25.
